Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Theragenex, a pharmaceutical development company, has signed a licensing agreement with Zylera Pharmaceuticals that covers a broad range of therapeutic areas including diabetes, cardiovascular diseases and osteoporosis.
Subscribe to our email newsletter
Specific financial terms of the transaction are confidential, however, both companies will share in resulting revenue.
“We are very excited about working with Zylera, as our patents are very complementary to their own R&D activities,” stated David Preston, chairman and CEO, Theragenex. “They are well down the road with several science-based pharmaceutical formulations that will benefit patients suffering from chronic diseases. We believe this technology licensing agreement accelerates the potential time to market of these product candidates.”
Theragenex is a life science and technology development company focused on acquiring patents and intellectual property addressing a wide range of therapeutic opportunities.